Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Research & Development (2016 - 2025)

Traws Pharma (TRAW) has disclosed Research & Development for 14 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 54.8% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.0 million, a 33.2% decrease, with the full-year FY2024 number at $12.8 million, up 12.4% from a year prior.
  • Research & Development was $2.3 million for Q3 2025 at Traws Pharma, up from $2.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.1 million in Q3 2024 to a low of $1.7 million in Q4 2021.
  • A 5-year average of $2.6 million and a median of $2.3 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 61.51% in 2021, then surged 116.22% in 2022.
  • Traws Pharma's Research & Development stood at $1.7 million in 2021, then skyrocketed by 116.22% to $3.8 million in 2022, then plummeted by 35.49% to $2.4 million in 2023, then decreased by 23.66% to $1.9 million in 2024, then rose by 24.38% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Research & Development are $2.3 million (Q3 2025), $2.3 million (Q2 2025), and $2.5 million (Q1 2025).